Literature DB >> 23494659

Potential of collagen-like triple helical peptides as drug carriers: Their in vivo distribution, metabolism, and excretion profiles in rodents.

Hiroyuki Yasui1, Chisato M Yamazaki, Hiroshi Nose, Chihiro Awada, Toshifumi Takao, Takaki Koide.   

Abstract

Collagen-model peptides composed of (X-Y-Gly)n sequences were used to study the triple helical structure of collagen. We report the stability of these collagen-like peptides in biological fluids, and their pharmacokinetics including distribution, metabolism, and excretion in animals. A typical collagen-model peptide, H-(Pro-Hyp-Gly)10-OH, was found to be extremely stable in the plasma and distributed mainly in the vascular blood space, and was eliminated through glomerular filtration in the kidneys. Triple helical peptides of (X-Y-Gly)n sequences were quantitatively recovered from the urine of rats after intravenous injection regardless of the differences in peptide net charge between -3 and +6 per triple helix. In contrast, the renal clearance became less efficient when the number of triplet repeats (n) was 12 or more. We also demonstrated the application of a collagen-like triple helical peptide as a novel drug carrier in the blood with a high urinary excretion profile. We further demonstrated that a collagen-like triple helical peptide conjugated to a spin probe, PROXYL, has the potential to evaluate the redox status of oxidative stress-induced animals in vivo.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  collagen; drug delivery; peptide; pharmacokinetics; triple helix

Mesh:

Substances:

Year:  2013        PMID: 23494659     DOI: 10.1002/bip.22234

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  8 in total

1.  High Serum Stability of Collagen Hybridizing Peptides and Their Fluorophore Conjugates.

Authors:  Lucas L Bennink; Daniel J Smith; Catherine A Foss; Martin G Pomper; Yang Li; S Michael Yu
Journal:  Mol Pharm       Date:  2017-05-08       Impact factor: 4.939

2.  Second Generation Triple-Helical Peptide Inhibitors of Matrix Metalloproteinases.

Authors:  Manishabrata Bhowmick; Dorota Tokmina-Roszyk; Lillian Onwuha-Ekpete; Kelli Harmon; Trista Robichaud; Rita Fuerst; Roma Stawikowska; Bjorn Steffensen; William Roush; Hector R Wong; Gregg B Fields
Journal:  J Med Chem       Date:  2017-04-19       Impact factor: 7.446

3.  Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues.

Authors:  Manishabrata Bhowmick; Roma Stawikowska; Dorota Tokmina-Roszyk; Gregg B Fields
Journal:  Chembiochem       Date:  2015-03-12       Impact factor: 3.164

4.  Dissecting MMP P10' and P11' subsite sequence preferences, utilizing a positional scanning, combinatorial triple-helical peptide library.

Authors:  Michal Tokmina-Roszyk; Gregg B Fields
Journal:  J Biol Chem       Date:  2018-09-05       Impact factor: 5.157

Review 5.  New strategies for targeting matrix metalloproteinases.

Authors:  Gregg B Fields
Journal:  Matrix Biol       Date:  2015-01-14       Impact factor: 11.583

6.  Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides.

Authors:  Jared L Zitnay; Yang Li; Zhao Qin; Boi Hoa San; Baptiste Depalle; Shawn P Reese; Markus J Buehler; S Michael Yu; Jeffrey A Weiss
Journal:  Nat Commun       Date:  2017-03-22       Impact factor: 14.919

Review 7.  Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.

Authors:  Gregg B Fields
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 8.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Authors:  Gregg B Fields
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.